In late 2008, this firm shut down operations and the following year - 2009 - its assets were acquired by Millipore. The acquisition provided Millipore with a bioinformatics-driven technology for developing antibodies. The firm indicated intend to use the EpiTag technology to develop a range of multiplex immunoassay kits that can be used with the Luminex xMAP platform, to which Millipore holds a license. The kits will enable researchers to "more efficiently measure, detect, and analyze proteins and cell signaling pathways, Epitome Biosystems had been founded by major players in the field of proteomic analysis to commercialize multiplex protein detection technologies licensed from engeneOS Corp. The companyâs technology employed proprietary arrays that allow for highly precise, parallel protein analyses in biological samples by using unique signature peptides to fingerprint the proteome. Tackling the problem of protein content had been limiting the protein array market to that point, VC backed and with a world-class Scientific Advisory Board, Epitome has seemed well positioned to become a leader in multiplex protein analysis. Epitome Biosystems approach had involved development of content for protein microarrays and other multiplex immunoassays. Using the proprietary EpiTagTM technology, Epitome could accurately predict unique peptide sequences to serve as immunogens for the generation of highly specific antibodies in an efficient manner. The antibodies could thenbe used as binders in multiplex assays. Unlike traditional methods, Epitome developsed the assay around the peptide epitopes used to generate the antibody. The result was discussed as a protein array syste
